Keywords: strong, ph, ii, data, novartis, menb, vacc

Strong Ph II data for Novartis' MenB vacc

Article | 26 May 2008

Print This

Swiss drug major Novartis says that new mid-stage data on MenB, its investigational recombinant meningococcal group B vaccine, support its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in